Equities analysts predict that Amicus Therapeutics, Inc. (NASDAQ:FOLD) will post sales of $14.56 million for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Amicus Therapeutics’ earnings, with the lowest sales estimate coming in at $13.63 million and the highest estimate coming in at $15.73 million. Amicus Therapeutics posted sales of $2.83 million during the same quarter last year, which suggests a positive year-over-year growth rate of 414.5%. The company is scheduled to report its next quarterly earnings results on Wednesday, March 7th.
According to Zacks, analysts expect that Amicus Therapeutics will report full-year sales of $14.56 million for the current financial year, with estimates ranging from $32.90 million to $37.13 million. For the next financial year, analysts expect that the business will post sales of $0.00 per share. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that cover Amicus Therapeutics.
Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.10). The business had revenue of $10.90 million during the quarter, compared to analyst estimates of $9.02 million. Amicus Therapeutics had a negative net margin of 1,092.37% and a negative return on equity of 63.54%. The business’s quarterly revenue was up 419.0% compared to the same quarter last year. During the same period last year, the business earned ($0.33) EPS.
Amicus Therapeutics (NASDAQ FOLD) traded up $0.37 on Friday, reaching $16.15. The company’s stock had a trading volume of 2,502,700 shares, compared to its average volume of 2,948,783. The firm has a market cap of $2,630.00, a price-to-earnings ratio of -8.83 and a beta of 1.72. The company has a debt-to-equity ratio of 0.39, a current ratio of 6.32 and a quick ratio of 6.22. Amicus Therapeutics has a 12-month low of $5.07 and a 12-month high of $16.60.
In related news, insider Jay Barth sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $13.59, for a total transaction of $67,950.00. Following the completion of the transaction, the insider now owns 69,184 shares in the company, valued at approximately $940,210.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO John F. Crowley sold 5,920 shares of the firm’s stock in a transaction that occurred on Saturday, December 29th. The stock was sold at an average price of $14.75, for a total value of $87,320.00. Following the transaction, the chief executive officer now owns 341,051 shares of the company’s stock, valued at approximately $5,030,502.25. The disclosure for this sale can be found here. Insiders have sold a total of 197,890 shares of company stock worth $2,767,181 in the last three months. 3.40% of the stock is owned by insiders.
Institutional investors have recently bought and sold shares of the stock. Alliancebernstein L.P. lifted its position in shares of Amicus Therapeutics by 16.3% during the 2nd quarter. Alliancebernstein L.P. now owns 205,836 shares of the biopharmaceutical company’s stock worth $2,073,000 after buying an additional 28,800 shares during the period. Bank of Nova Scotia bought a new position in shares of Amicus Therapeutics during the 2nd quarter worth approximately $1,944,000. American International Group Inc. lifted its position in shares of Amicus Therapeutics by 23.1% during the 3rd quarter. American International Group Inc. now owns 109,628 shares of the biopharmaceutical company’s stock worth $1,653,000 after buying an additional 20,597 shares during the period. Redmile Group LLC lifted its position in shares of Amicus Therapeutics by 5.9% during the 2nd quarter. Redmile Group LLC now owns 12,043,932 shares of the biopharmaceutical company’s stock worth $121,282,000 after buying an additional 668,080 shares during the period. Finally, Vanguard Group Inc. lifted its position in shares of Amicus Therapeutics by 5.0% during the 2nd quarter. Vanguard Group Inc. now owns 9,118,246 shares of the biopharmaceutical company’s stock worth $91,821,000 after buying an additional 430,486 shares during the period.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.